Navigation Links
Seminar Spotlights Key Trends in Biologics and Biosimilars
Date:3/12/2013

BURLINGTON, Mass., March 12, 2013 /PRNewswire/ -- Decision Resources Group (DRG) invites pharmaceutical professionals to a one-day seminar of in-depth analysis covering key issues in the biologics and biosimilars market. The seminar, which will include presentations from prominent DRG analysts and an industry panel discussion, will be held May 2, 2013 at Hotel Solamar in San Diego, CA.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36768LOGO )

Andrew Merron , Ph.D., Director of the Biosimilars Advisory Service at Decision Resources Group, a recognized expert in the area of biologics and biosimilars, explained the timeliness of the seminar. "Though the first generation of biosimilar products experienced mixed commercial success in Europe, substantial commercial opportunity remains for future biosimilar agents across a wide variety of indications and new biologics continue to carve out niches and evolve current standards of care,"  said Dr. Merron.

Presentations at the seminar will address market trends and opportunities. Dr. Merron noted, "Sales of biologics have continued to grow globally despite increasing competition from biosimilars. However, developers of new branded biologics are now challenged to demonstrate clinical differentiation and developers of biosimilars are challenged to meet robust clinical comparability requirements."

This seminar is intended for pharmaceutical professionals involved in market research, business development and competitive intelligence.  Attendees are invited to engage with analysts and peers with a post-event reception

For more information about the topics and speakers at the seminar go to http://www.competitivelandscapeseries.com/biologics-and-biosimilars/index.html   

Media Contact
Media interested in further information or in attending the seminar should contact Roy Strunin at rstrunin@dresources.com or (781) 993-2515.

About the Competitive Landscape Seminar Series
The Competitive Landscape Seminar Series: Biologics and Biosimilars will be held on May 2, 2013. This high-value, one-day seminar has been developed specifically for biopharmaceutical market research executives as well as biologics and biosimilars product teams. Expert analysts from Decision Resources Group companies—Decision Resources and BioTrends Research Group—will share their latest research findings on key biologics and biosimilars trends.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

Decision Resources Group
Roy Strunin
781-993-2515
rstrunin@dresources.com


'/>"/>
SOURCE Decision Resources Group
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. iBioSeminars and iBioMagazine: Free, Online Biology Seminars and Short Talks by Leading Scientists
2. ComplianceOnline Announces Seminar on Clinical Trial Project Supplier Quality Improvement
3. ComplianceOnline Announces Seminar on Statistical Analysis for Product Development
4. Patheon to Host Complimentary Seminar on “Getting Your Drug through Phase I Early Development Effectively” at Milton Park, UK Facility
5. BioSpace Spotlights Northwests Life Science Community
6. BioSpace Spotlights Leading Life Science Community
7. FasterCures Spotlights Addario Lung Cancer Medical Institutes Innovative Research Programs
8. BioSpace Spotlights the growing Midwest Life Science Community
9. BioSpace Spotlights Thriving Bay Area Life Science Community
10. BioSpace Spotlights Northwests Life Science Community
11. ResearchMoz: MicroRNA Market Trends 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Global demand for ... percent through 2020 to $7.2 billion.  This market ... beverages, cleaning products, biofuel production, animal feed, and ... diagnostics, and biocatalysts). Food and beverages will remain ... by increasing consumption of products containing enzymes in ...
(Date:6/27/2016)... , ... June 27, 2016 , ... ... bring innovative medical technologies, services and solutions to the healthcare market. The company's ... of various distribution, manufacturing, sales and marketing strategies that are necessary to help ...
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
Breaking Biology Technology:
(Date:5/20/2016)...  VoiceIt is excited to announce its new ... By working together, VoiceIt and VoicePass will offer ... take slightly different approaches to voice biometrics, collaboration ... usability. Both ... "This marketing and technology partnership allows ...
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
(Date:4/26/2016)... 27, 2016 Research and ... Biometrics Market 2016-2020"  report to their offering.  , ... The analysts forecast the global multimodal biometrics ... during the period 2016-2020.  Multimodal biometrics ... such as the healthcare, BFSI, transportation, automotive, and ...
Breaking Biology News(10 mins):